Clinical Trials

Prostate Cancer, Hereditary, 7, Prostatic Neoplasms

NCT05806515 2026-01-29

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

44 enrolled

Prostatic Neoplasms

NCT06470243 2026-01-22

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

Phase 3 Recruiting

528 enrolled

Prostatic Neoplasms

NCT06039371 2026-01-14

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

69 enrolled

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04592237 2025-12-23

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

120 enrolled

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT03582475 2025-11-12

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

15 enrolled 17 charts

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Prostatic Neoplasms, Urethral Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

126 enrolled

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT06738303 2025-08-27

CATCH-177

44 enrolled

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03385655 2025-08-21

Prostate Cancer Biomarker Enrichment and Treatment Selection

200 enrolled

Prostatic Neoplasms

NCT04038502 2025-08-20

COBRA

Classical hematologyGenitourinary

100 enrolled

Fanconi Anemia, Complementation Group N, Fanconi Anemia, Complementation Group D1, Hereditary Sensory and Autonomic Neuropathies, Prostatic Neoplasms

NCT06864533 2025-04-24

PKUFH-GS5

Phase NA Recruiting

315 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Prostatic Neoplasms

NCT02009449 2024-11-15

IVY

Phase 1 Completed

353 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02903160 2024-02-07

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

40 enrolled 18 charts

Phase EARLY_PHASE1 Withdrawn

Neoplasm Metastasis, Prostatic Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT02598895 2022-11-17

Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway

14 enrolled 8 charts

Prostatic Neoplasms

NCT02565901 2021-10-01

Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Terminated

28 enrolled 8 charts

Prostatic Neoplasms

NCT02985021 2021-08-05

Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies

Phase 2 Terminated

2 enrolled 5 charts

Prostatic Neoplasms

NCT01505868 2021-07-30

Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Completed

170 enrolled 22 charts

Lymphadenopathy, Prostatic Neoplasms

NCT01051570 2020-12-01

Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel

26 enrolled 9 charts

Prostatic Neoplasms

NCT00049257 2020-09-01

Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

58 enrolled 9 charts

Prostatic Neoplasms

NCT00514540 2020-09-01

Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer

121 enrolled 8 charts

Prostatic Neoplasms

NCT02311764 2020-01-23

PRO-PLAT

Phase 2 Terminated

16 enrolled

Prostatic Neoplasms

NCT01558492 2017-06-09

Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer

Phase 2 Terminated

3 enrolled 3 charts

Prostatic Neoplasms

NCT00017576 2017-04-28

Calcitriol and Carboplatin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

19 enrolled

Prostatic Neoplasms

NCT00005810 2016-07-14

Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

40 enrolled

Prostatic Neoplasms

NCT00016913 2016-07-06

Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer

34 enrolled 5 charts

Prostatic Neoplasms

NCT00005627 2013-07-18

Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 1 Completed

Prostatic Neoplasms

NCT00003394 2013-06-24

Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer

Phase 1/2 Completed

18 enrolled

GenitourinaryOther solid neoplasmThoracic

Prostatic Neoplasms

NCT01604863 2012-11-01

A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies

Phase 1 Suspended

54 enrolled

Lung Neoplasms, Mesothelioma, Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT00973882 2011-11-03

Carboplatin-Etoposide Combination in Hormone-Resistant Prostate Cancers

60 enrolled

BreastDermatologicGenitourinary

Prostatic Neoplasms

NCT00003690 2011-08-03

Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

48 enrolled

Breast Neoplasms, Melanoma, Prostatic Neoplasms

NCT00193193 2010-08-04

Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma

100 enrolled

Prostatic Neoplasms

NCT00134706 2009-12-09

A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer

30 enrolled